Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, Liu R, Zou W.

Immunity. 2013 Sep 19;39(3):611-21. doi: 10.1016/j.immuni.2013.08.025. Epub 2013 Sep 5.


BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.

May T, Yang J, Shoni M, Liu S, He H, Gali R, Ng SK, Crum C, Berkowitz RS, Ng SW.

Neoplasia. 2013 Jun;15(6):600-8.


Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.

Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X.

J Immunol. 2013 Apr 1;190(7):3783-97. doi: 10.4049/jimmunol.1201449. Epub 2013 Feb 25.


Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.

Höchst B, Schildberg FA, Sauerborn P, Gäbel YA, Gevensleben H, Goltz D, Heukamp LC, Türler A, Ballmaier M, Gieseke F, Müller I, Kalff J, Kurts C, Knolle PA, Diehl L.

J Hepatol. 2013 Sep;59(3):528-35. doi: 10.1016/j.jhep.2013.04.033. Epub 2013 May 9.


C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.

Barroilhet L, Yang J, Hasselblatt K, Paranal RM, Ng SK, Rauh-Hain JA, Welch WR, Bradner JE, Berkowitz RS, Ng SW.

Oncogene. 2013 Aug 15;32(33):3896-903. doi: 10.1038/onc.2012.380. Epub 2012 Sep 3.


Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.

Birts CN, Harding R, Soosaipillai G, Halder T, Azim-Araghi A, Darley M, Cutress RI, Bateman AC, Blaydes JP.

Biol Cell. 2010 Jan;103(1):1-19. doi: 10.1042/BC20100067.


Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P.

Blood. 2011 Nov 17;118(20):5498-505. doi: 10.1182/blood-2011-07-365825. Epub 2011 Oct 4.


Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.

Ye XZ, Yu SC, Bian XW.

J Genet Genomics. 2010 Jul;37(7):423-30. doi: 10.1016/S1673-8527(09)60061-8.


Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration.

Wang Y, Liu F, Mao F, Hang Q, Huang X, He S, Wang Y, Cheng C, Wang H, Xu G, Zhang T, Shen A.

J Biol Chem. 2013 Mar 29;288(13):9028-34. doi: 10.1074/jbc.M112.432005. Epub 2013 Feb 7.


Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.

Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G.

Urol Oncol. 2014 May;32(4):426-32. doi: 10.1016/j.urolonc.2013.09.006. Epub 2013 Dec 12.


Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression.

Zhang M, Liu Q, Mi S, Liang X, Zhang Z, Su X, Liu J, Chen Y, Wang M, Zhang Y, Guo F, Zhang Z, Yang R.

J Immunol. 2011 Apr 15;186(8):4716-24. doi: 10.4049/jimmunol.1002989. Epub 2011 Mar 7.


Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA.

Blood. 2008 Apr 15;111(8):4233-44. doi: 10.1182/blood-2007-07-099226. Epub 2008 Feb 13.


Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S.

Blood. 2011 May 19;117(20):5381-90. doi: 10.1182/blood-2010-11-321752. Epub 2011 Mar 30.


CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.

Zhang C, Gao C, Xu Y, Zhang Z.

Gene. 2014 Aug 1;546(1):73-9. doi: 10.1016/j.gene.2014.05.032. Epub 2014 May 14.


Obesity-Associated MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2 and Releasing C/EBPα from CtBP2 Binding.

Wang L, Xu L, Xu M, Liu G, Xing J, Sun C, Ding H.

Cell Physiol Biochem. 2015;35(6):2285-98. doi: 10.1159/000374032. Epub 2015 Apr 13.


[Detection and correlation analysis of miRNAs and myeloid-derived suppressor cells in ovarian cancer-bearing mice].

Liu Y, Lin X, Bao T, Ni P, Xie C, Shen H, Xu W, Xu H, Su Z.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Apr;31(4):467-9, 473. Chinese.


Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer.

Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC.

Cancer Immunol Immunother. 2014 May;63(5):513-28. doi: 10.1007/s00262-014-1527-x. Epub 2014 Mar 21.


Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.

Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K.

PLoS One. 2013;8(2):e57114. doi: 10.1371/journal.pone.0057114. Epub 2013 Feb 20.


Antigen specificity of immune suppression by myeloid-derived suppressor cells.

Solito S, Bronte V, Mandruzzato S.

J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12. Review.


Supplemental Content

Support Center